EU-Israel Pact Recognizes Shared GMP Standards, Inspection Procedures

January 25, 2013

The EU and Israel have aligned their good manufacturing practice (GMP) standards and procedures for drug products and plant inspections, the European Medicines Agency (EMA) says.

The agreement on conformity assessment and acceptance (ACAA) allows EU-certified drugs to be exported to Israel and vice-versa without requiring additional certification for the importing country. The accord is intended to cut manufacturers’ costs and bring products to market faster.

The deal applies to finished drugs, active pharmaceutical ingredients and excipients. It does not apply to INDs, homeopathic drugs or special products based on human tissues, blood and cells.

Enforcement activities, practices and even staff are changing around the globe. The day-to-day routine drugmakers are used to when dealing with international regulators is changing and to be successful, you will need to know as much as possible.

With FDAnews’ Guide to International Pharma Regulation: 2013 Edition, you will receive briefs on regulatory developments affecting pharmaceutical production in more than 45 nations around the world. You also gain access to a compilation of more than 150 reports highlighting changes from the past year that could supercharge your international sales.

To compete internationally, you must comply internationally. It’s a lesson your competitors have learned. Don’t get left behind. Place your order now.